dry/wet Age-related Macular Degeneration(AMD) Treatment
OLX301A aims to be a first-in-class therapeutics for treating both dry and wet age-related macular degeneration (AMD). The program targets a gene that plays a major role in retinal pigment epithelium (RPE) cell damage.
Currently, there are no approved therapies to treat patients with both geographic atrophy (GA) and wet AMD, and one drug approved for GA is with concern regarding its efficacy. OLX301A has the potential to be a novel drug for wet AMD patients who is not responsive to conventional VEGF therapies.
Target RNA: Undisclosed
Administration Route: Intravitreal Injection
Age-related Macular Degeneration(AMD)
AMD is a degenerative disease that causes abnormalities in the central part of the retina, leading to vision loss.
The disease usually comes with age. When retina cells start to lose their function, metabolic wastes accumulate,
impairing the choroidal blood supply function and eventually leading to cellular atrophy/choroidal neovascularization (CNV).
While earlier stages of the disease (including the GA stage without CNV) are categorized as dry AMD, later-stage AMD with vascular leakage is classified as wet AMD.
- Outstanding efficacy identified in animal models with dry/wet AMD
- KNDA(Korea New Drug Award) (21.03)
- Phase 1 clinical trial in progress (US)
Title Link A Phase 1, Multicenter, Open-Label, Single- and Multi-Dose, Dose-Escalating Clinical Study to Evaluate the Safety and Tolerability of OLX10212 Administered by Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (AMD) Learn More
- 2021 CSHL(Cold Spring Harbor Laboratory)-Nucleic Acid Therapies (21.03)
- 2021 OTS (Oligonucleotide Therapeutics Society) (21.09)
- 2022 OTS (Oligonucleotide Therapeutics Society) (22.10)